Hey
@mitchlol
Welcome, your attachment refers to a class three device...rap is going for a class two, not sure if that helps or not..
Refer the sp...my feeling is many weak hands have long gone, the results from the three top tier hospitals will govern the short term SP big time...the reason??
- great results will ensure FDA slam dunk.
- Being endorsed by world leading partners will do more for SP than post FDA
- The following media attention from trial results will drive SP
- The fact that more one illlness apart from child pneumonia will be submitted, its being mentioned numerous time re Ann's
I'm not suggesting there won't be a retrace after the first or second break out...the real kicker is going to be post FDA when Telehealth non exclusive agreements are signed left right and centre, which will in turn allow for projected revenue to be calculated....remember our income stream will be faster than a fat dude at sizzler.......
my stab in the future is 40-60c pre FDA & 90-130c late in the year...this guess is only allowing for one revenue stream...the mind boggles...merry Christmas
I thought they meant that it's within 120 days they need to classify a device as class I II or III.
